Viatris has agreed to acquire Pacira BioSciences in a deal valued at about $1.65 billion. The offer is $36.50 per share, which sources describe as roughly a 45% premium. After the announcement, Pacira shares jump sharply, with one outlet reporting a rise of about 44%.
The acquisition is positioned as part of Viatris’s push in non-opioid pain medicines. Multiple outlets say the deal expands Viatris’s pain-drug portfolio and includes two non-opioid treatments that together generated close to $700 million in 2025, according to one report. Some coverage also notes that the medicines could face changing competitive conditions as patent protection approaches. Viatris says it plans to apply its intellectual property expertise to support continued sales. The parties expect the transaction to close by the end of 2026.
